Clinical Quality Indicators

Similar documents
US Public Health Service Clinical Practice Guidelines for PrEP

iprex Fact Sheet: Key Results

PrEP Home Checklist v1.0

Waterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

Table of Contents (Click on title to jump to section)

Evaluation of Hunter & New England HealthPathways

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

CDC Influenza Technical Key Points February 15, 2018

Center for Circulatory Support. The Center for Circulatory Support strives for continuous improvement in quality and patient outcomes

Chapter 6: Impact Indicators

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

Significance of Chronic Kidney Disease in 2015

Trillium and Willamette Dental Group: Dental-Medical Diabetes Management and Care Coordination

The research question: What was discovered in the 1940s that could treat syphilis?

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

HPV VACCINATION IN SANDYFORD SERVICES

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

ACRIN 6666 Screening Breast US Follow-up Assessment Form

CDC Influenza Division Key Points MMWR Updates February 20, 2014

Chronic Fatigue Syndrome

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Diabetes: HbA1c Poor Control (NQF 0059)

Hearing Service Fees and Fee Codes Effective: January 01, 2019

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Implementation of Early retention monitoring of HIV positive pregnant and breastfeeding women; and data use in the EMTCT program MOH-UGANDA

Referral Criteria: Inflammation of the Spine Feb

NATIONAL GUIDELINES ON THE USE OF ANTIRETROVIRAL THERAPY FOR HIV PREVENTION AND TREATMENT

Nonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

2017 CMS Web Interface

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute

Lyme Disease Surveillance in North Carolina

Child and Adult Preventive Care Services

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

Solid Organ Transplant Benefits to Change for Texas Medicaid

HIV Diagnostic Tests. HIV Testing Algorithm at SydPath (National Reference Laboratory)

COMMUNITY (NON-OCCUPATIONAL) BLOOD OR BODILY FLUID EXPOSURE

Colorado Essential Health Benefit for Children

Cognitive enhancers for the treatment of Alzheimer s disease

Tick fever is a cattle disease caused by any one of the following blood parasites:

Section 5. Study Procedures

Alberta Health Public Health Notifiable Disease Management Guidelines April 2013

2018 CMS Web Interface

COPD Outreach Program

New London County Unified Intake for Homeless Families

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

BRCA1 and BRCA2 Mutations

Choose to participate Enroll yourself and family members Waive coverage

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain

Commissioning Policy: South Warwickshire CCG (SWCCG)

HCV exposure, infection and associated risk behaviours in two maximumsecurity prisons in NSW, Australia

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

<Date> <Group> <Address1> <Address2> <City> <State> <zip> RE: 2015 Blue Physician Recognition (BPR) Program. Dear <Group>:

APPENDIX A Certification of Advanced Disease:

Administrstrative Procedure

Cambridge Breast Unit Protocols for anticoagulant management prior to breast or axillary biopsies or excisions.

Clinical Study Synopsis

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

2018 Medical Association Poster Symposium Guidelines

Billing Preventive Services June 6, 2017

LTCH QUALITY REPORTING PROGRAM

REFERRAL GUIDELINES Upper Gastro-Intestinal & Hepaticobilary

SUICIDE AND MENTAL ILLNESS IN SINGAPORE

My Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)

2017 CMS Web Interface

FTD RESEARCH: The Value of Studies and Opportunities for Involvement

Limitations and Exclusions (What is Not Covered)

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion

Diabetes Mellitus Lab Tests (Screening, Diagnosis & Monitoring)

Smoking Cessation Improvement in SFHN Primary Care,

STI Indicators by STI

Fast-Track Your PrEP Knowledge. Jonathan Fritz PrEP Coordinator MDHHS Division of HIV and STD Programs

Malaria 2025: Accelerate to Eliminate The Global Technical Strategy for Malaria: Setting global targets Azra Ghani, GTS Steering Committee

Swindon Joint Strategic Needs Assessment Bulletin

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Howard E. Gary, Jr., Ray Sanders, and Mark A. Pallansch. Methods

Opioid Analgesics PA Request Provider Checklist

APESB and Auditor Independence

Drug Therapy Guidelines

THE SOUTH AFRICAN ANTIRETROVIRALTREATMENT GUIDELINES 2013

Urinary tract infection (lower) - women - Management

Childhood Immunization Status (NQF 0038)

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator

Drug Therapy Guidelines

Cardiac Rehabilitation Services

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

A. Catalonia World Health Organization Demonstration Project

Osteoporosis Fast Facts

GP Perspective about prescribing PEP & PrEP

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics

Response to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

CONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW

Drug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)

GAY MEN/MSM AND STD S IN NJ: TAKE BETTER CARE OF YOUR PATIENTS! STEVEN DUNAGAN SPECIAL PROJECTS COORDINATOR NJ DOH STD PROGRAM SEPTEMBER 27, 2016

Transcription:

Clinical Quality Indicatrs Patients currently n PrEP Patients currently n PrEP Definitins: Eligibility: Any patient wh has been prescribed PrEP during the review perid. Risk Assessment Prprtin f patients wh received a risk assessment regarding histry f cndm usage, STI, intravenus drug use, transactinal sex, and Nn-ccupatinal Pst-Expsure Prphylaxis (npep) at baseline and every 4 mnths afterwards. All patients Number f patients wh received a risk assessment at least every 4 mnths Risk assessments include: Cndm usage STI histry Intravenus drug use histry Transactinal sex histry Nn-ccupatinal Pst-Expsure Prphylaxis (npep) histry HIV Testing Prprtin f patients wh received an HIV test at baseline and every 4 mnths afterwards. All patients Number f patients wh received an HIV test at baseline and at least every 4 mnths HIV Sercnversin Prprtin f patients wh test psitive fr HIV. All patients wh were tested fr HIV Number f patients wh test psitive fr HIV while n PrEP STI Screening Prprtin f patients wh received a syphilis, gnrrhea, and chlamydia tests at baseline and every 4 mnths. All patients Number f patients wh received syphilis, gnrrhea, and chlamydia tests at baseline and at least every 4 mnths

Rectal Chlamydia Testing Prprtin f patients wh received a rectal chlamydia test every 4 mnths. All patients engaging in anal sex Number f patients wh were tested fr rectal chlamydia at least every 4 mnths Rectal Gnrrhea Testing Prprtin f patients wh received a rectal gnrrhea test every 4 mnths. All patients engaging in anal sex Number f patients wh were tested fr rectal gnrrhea at least every 4 mnths Pharyngeal Gnrrhea Testing Prprtin f patients wh received a pharyngeal gnrrhea test every 4 mnths. All patients engaging in ral sex Number f patients wh were tested fr pharyngeal gnrrhea at least every 4 mnths Renal Functin Screening Prprtin f patients whse renal functin was assessed fr serum creatinine at baseline and every 6 mnths. All patients Number f patients wh received a serum creatinine test at baseline and every 6 mnths Urinalysis Prprtin f patients wh received a urinalysis at baseline and every 6 mnths. All patients Number f patients wh received a urinalysis at baseline and every 6 mnths Adherence Assessment Prprtin f patients wh received an adherence assessment every 4 mnths. All patients Number f patients wh received an adherence assessment every 4 mnths Mental Health Screening Prprtin f patients wh received a baseline and annual mental health screening. All patients Number f patients wh received a baseline and annual mental health screening

Substance Abuse Screening Prprtin f patients wh received a baseline and annual substance abuse screening. All patients Number f patients wh received a baseline and annual substance abuse screening Dmestic Vilence Screening Prprtin f patients wh received a baseline and annual dmestic vilence screening. All patients Number f patients wh received a baseline and annual dmestic vilence screening Linkage t care Prprtin f patients wh sercnverted and were linked t HIV care within 5 days. All patients wh sercnverted Number f patients wh were linked t HIV care within 5 days f sercnversin

Patients wh have nt started PrEP Patients wh have nt started PrEP Eligibility: Patients wh have nt been prescribed PrEP but are currently enrlled in the PrEP prgram during the review perid. Risk Assessment Prprtin f patients wh received a risk assessment regarding histry f cndm usage, STI, intravenus drug use, transactinal sex, and Nn-ccupatinal Pst-Expsure Prphylaxis (npep) at baseline and every 4 mnths afterwards. All patients Number f patients wh received a risk assessment at least every 4 mnths Risk assessments include: Cndm usage STI histry Intravenus drug use histry Transactinal sex histry Nn-ccupatinal Pst-Expsure Prphylaxis (npep) histry HIV Testing Prprtin f patients wh received an HIV test every 4 mnths. All patients Number f patients wh received an HIV test at least every 4 mnths HIV Testing: HIV Sercnversin (nt n PrEP) Prprtin f patients testing psitive fr HIV. All patients wh were tested fr HIV Number f patients wh test psitive fr HIV Exclusins: Patients with a knwn HIV infectin. Linkage t care (Sercnversins) Prprtin f patients wh sercnverted and were linked t HIV care within 5 days. All patients wh sercnverted Number f patients wh were linked t HIV care within 5 days f sercnversin STI Screening Prprtin f patients wh received a syphilis, gnrrhea, and chlamydia tests at baseline and every 4 mnths.

All patients Number f patients wh received syphilis, gnrrhea, and chlamydia tests at baseline and at least every 4 mnths Rectal Chlamydia Testing Prprtin f patients wh received a rectal chlamydia test every 4 mnths. All patients engaging in anal sex Number f patients wh were tested fr rectal chlamydia at least every 4 mnths Rectal Gnrrhea Testing Prprtin f patients wh received a rectal gnrrhea test every 4 mnths. All patients engaging in anal sex Number f patients wh were tested fr rectal gnrrhea at least every 4 mnths Pharyngeal Gnrrhea Testing Prprtin f patients wh received a pharyngeal gnrrhea test every 4 mnths. All patients engaging in ral sex Number f patients wh were tested fr pharyngeal gnrrhea at least every 4 mnths

General Clinic-Specific Quality Indicatrs Clinic level Indicatrs Clinic Level Eligibility: Patients are thse wh: Are in a serdiscrdant relatinships Reprt having cndmless sex Had an STI within the past 6 mnths Have injected drugs within the past 6 mnths Identify as transgender and engage in high-risk sex Engage in transactinal sex Have been prescribed nn-ccupatinal pst-expsure prphylaxis (npep). Rutine Offering f PrEP Prprtin f at risk patients wh were ffered PrEP. All patients Number f patients wh were ffered PrEP services Patient Experience Indicatrs Patient Experience Eligibility: All patients enrlled in the PrEP prgram. Patient Experience Prprtin f patients wh were assessed fr experience. All patients Number f patients were assessed fr experience Stigma Prprtin f patients wh reprted experiences f stigma when receiving PrEP services. All patients Number f patients wh reprted experiences f stigma assciated with receiving PrEP services Access t Medicatin Prprtin f patients reprting gaps in medicatin adherence. All patients wh have been prescribed PrEP Number f patients wh reprted gaps in medicatin adherence

Organizatinal Metrics Organizatinal Indicatrs Onging Staff Training Staff receiving annual PrEP training. All staff prviding HIV care Number f staff that receive annual PrEP training Stigma Reductin Training Staff receiving annual stigma reductin training. All staff prviding HIV care Number f staff that receive annual stigma reductin training Referral and Linkage Prprtin f patients wh were linked t primary care after stpping PrEP. Patients that have stpped taking PrEP within the review perid Number f patients that are linked and referred t primary care Exclusins: Sites with an integrated PrEP and primary care prgram. Lst t Care Prprtin f patients wh were reengaged in care after missing 2 r mre cnsecutive PrEP clinical appintments. All PrEP patients wh have missed 2 r mre cnsecutive PrEP clinical appintments Number f patients reengaged in care

Ppulatin Indicatrs Patients with STIs Prprtin f patients wh test psitive fr STIs. All patients receiving services in a PrEP prgram Number f STIs Incidence rate f STIs fr PrEP patients. All patients receiving services in a PrEP prgram Number f patients wh test psitive fr STIs Number f cnfirmed unique diagnses f STIs Linkage t Care Prprtin f identified PrEP eligible patients wh were linked t PrEP services. Patients wh: Number f patients wh were linked t Are in a serdiscrdant relatinships PrEP services Reprt having cndmless sex Had an STI within the past 6 mnths Have injected drugs within the past 6 mnths Identify as transgender and engage in highrisk sex Engage in transactinal sex Have been prescribed nn-ccupatinal pstexpsure prphylaxis (npep).